Antisense Oligonucleotides Market Outlook 2025

Antisense oligonucleotides are short, single stranded RNA or DNA molecules. Antisense oligonucleotides do not modulate the activity of already formed proteins, however they act before proteins are produced at the level of messenger RNA in the cell. Antisense oligonucleotides is used in treatment of oncology, Central nervous system therapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc. Antisense oligonucleotides is also used in genomics. Some examples of antisense nucleotides are fomivirsen to treat cytomegalovirus retinitis, mipomersen to treat high cholesterol, etc.

Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1879

Antisense Oligonucleotides Market Drivers:-

One of the major factors driving growth of the global antisense oligonucleotides market is increasing number of launches pertaining to novel Antisense Oligonucleotides products by key players in the market. For instance, in 2015, Exiqon A/S acquired by Qiagen launched new LNA Antisense Oligonucleotide GapmeRs. LNA Antisense Oligonucleotide GapmeRs is used for inactivation of RNA in functional analysis. Antisense LNA is an alternative to existing siRNAs. LNA Antisense Oligonucleotide are designed using advanced bioinformatics algorithm, which is combined with LNA (locked nucleic acid).

Furthermore, mergers and acquisitions by key players, in order to enhance their product offerings is expected to be a major driver for global antisense oligonucleotides market growth. For instance, in February 2018, Takeda Pharmaceuticals Company Ltd.—a pharmaceutical company—merged with Wave Life Sciences Ltd., which is involved in nuclei acid therapeutics. Takeda Pharmaceuticals has merged with Wave Life Sciences Ltd. to develop antisense oligonucleotides for central nervous system disorder, which includes Lou Gehrig’s disease, Frontotemporal dementia (FTD), Spinocerebellar ataxia type 3 (SCA3), and huntington’s disease. Lou Gehrig’s disease is also called as Amyotrophic lateral sclerosis (ALS). This acquisition will also help Takeda in gaining market share.

Antisense Oligonucleotides Market Regional Analysis:-

North America is expected to be the dominant region in the global antisense oligonucleotides market over the forecast period. This is owing to increasing approvals of new antisense oligonucleotide drugs in the region. For instance, in 2018, U.S. FDA approved Nusinersen, which is marketed as Spinraza from Biogen Inc.—a multinational biotechnology company. Nusinersen is the first drug approved for the treatment of Spinal muscular Atrophy (SMA). Moreover, robust pipeline is expected to contribute significantly to North America antisense oligonucleotides market growth. For instance, in 2017, Bio Path Holding’s—an oncology focused biotechnology company— drug BP 1001 (liposomal Grb2 antisense oligonucleotide) was in phase 2 clinical trials. BP 1001 (liposomal Grb2 antisense oligonucleotide) is used to treat chronic myelogenous leukemia.

Antisense Oligonucleotides Market Key Players:-

Key players in global antisense oligonucleotides market include Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation, Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi Pharmaceuticals Inc.

Request for TOC : https://www.coherentmarketinsights.com/ongoing-insight/toc/1879

Antisense Oligonucleotides Market Taxonomy:-

By Drugs:-

  • Pegaptanib
  • Eteplirsen
  • Mipomersen
  • Others

By Therapeutic Application-

  • Cancer
  • Diabetes
  • Ocular diseases
  • Amyotrophic Lateral Sclerosis (ALS)
  • Spinal Muscular Atrophy
  • Hemorrhagic fever viruses
  • HIV/AIDS
  • Cytomegalovirus retinitis
  • Others

By Distribution Channel:-

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies

By Region:-

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa

Request For Customization : https://www.coherentmarketinsights.com/insight/request-discount/1879

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com



Reset Password